Browse Category

NYSE:AZN News 16 September 2025 - 1 February 2026

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca shares closed in London at 135.48 pounds Friday, up 0.65%. The company moves its U.S. listing from Nasdaq to the NYSE on Monday, keeping the AZN ticker. AstraZeneca recently announced a $1.2 billion obesity drug deal with CSPC and pledged $15 billion investment in China by 2030. Investors await full-year results on Feb. 10.
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and other firms of funding terrorism in Iraq. The ruling was announced after U.S. markets closed; AstraZeneca shares had closed up 1.37% in New York and 0.15% in London. The company plans to switch its U.S. listing from Nasdaq to NYSE on Jan. 30. Investors await Monday’s market reaction.
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca shares fell 4.4% to $90.23 Tuesday after the company said it will delist its American depositary shares from Nasdaq and move to a direct listing of ordinary shares on the NYSE starting February 2. The switch, set for after markets close January 30, comes as European stocks face pressure from U.S. tariff threats. AstraZeneca’s London shares also dropped 2.6%.
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

LONDON, Dec. 7, 2025 — The MSCI Europe Index slipped modestly at the end of the week but remains one of 2025’s equity standouts, still ahead of broad global benchmarks such as the MSCI World and MSCI ACWI. European stocks are pausing after a powerful rally, even as fresh forecasts from major banks signal further upside into 2026 and technical indicators continue to lean constructive. MSCI Europe Index: Latest Performance Snapshot At Friday’s close on 5 December 2025, the MSCI Europe Index (MIEU00000PUS) finished at 2,564.76, down 0.25% on the day after three sessions of gains. Investing.com Despite that small
Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce (NYSE: CRM) has triggered a fresh wave of headlines after posting record third‑quarter fiscal 2026 results, raising its full‑year outlook and signing a high‑profile AI deal with AstraZeneca. Yet despite the post‑earnings stock pop and new enterprise wins, CEO Marc Benioff is still fighting to convince Wall Street that Salesforce’s aggressive artificial intelligence strategy will translate into lasting shareholder returns. Salesforce Investor Relations+2Reuters+2 Q3 2026 by the numbers: record revenue, fatter margins For its fiscal third quarter ended October 31, 2025, Salesforce reported: On the bottom line, Salesforce delivered adjusted EPS of $3.25, handily beating the roughly $2.86 Wall
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA (NASDAQ: ABVX), the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have ranged between about $113.63 and $126.42, on heavy volume of roughly 3.7 million American Depositary Shares (ADSs). Stock Invest That move adds to what has already been one of the biggest biotech runs of 2025. Abivax is up more than
20 November 2025
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will

Stock Market Today

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Go toTop